Arava

Arava is a disease-modifying antirheumatic drug (DMARD) used for inflammatory arthritis, mainly rheumatoid arthritis and psoriatic arthritis in adults. The generic name of Arava is leflunomide, and its goal is to control the immune-driven process behind swelling, pain, and progressive joint damage rather than only masking symptoms.

Arava is usually considered when joints are actively inflamed and morning stiffness, swelling, and fatigue are affecting daily function. It can be used as a long-term controller medicine, so expectations should be realistic: this is a “slow-burn” therapy, not a fast painkiller ^[1].

Arava, with the active ingredient leflunomide, is an oral DMARD used to treat active rheumatoid arthritis and psoriatic arthritis in adults.

Arava is supplied as tablets. On this page, Arava is available in 10 mg and 20 mg tablet strengths, which are the usual maintenance-dose strengths used in rheumatoid arthritis and psoriatic arthritis care.

Film coating is used to make tablets easier to swallow and to reduce taste irritation. Tablets are intended to be swallowed whole with water.

Arava is taken by mouth once daily. That schedule is simple. A common adult regimen begins with a loading dose of 100 mg once daily for the first 3 days, then transitions to a maintenance dose of 20 mg once daily. The maintenance dose can be reduced to 10 mg once daily if side effects limit tolerance.

Key administration points that matter in real life:

• Take it at roughly the same time each day to reduce missed doses.
• Food is optional; consistency helps if your stomach is sensitive.
• Treatment duration is long-term, and symptom improvement is usually gradual rather than immediate.

A missed dose is usually handled by taking the next scheduled dose at the usual time rather than doubling up, since doubling increases side-effect risk without improving control.

• Route: oral tablets
• Dose: 100 mg by mouth once daily for the first 3 days, then 20 mg by mouth once daily as the maintenance dose
• Timing: take at the same time each day, with or without food
• Duration: long-term treatment as prescribed by a rheumatology clinician
• Administration: swallow the tablet whole with water

Arava is indicated for the treatment of active rheumatoid arthritis in adults to reduce signs and symptoms, improve physical function, and help slow progression of joint damage. It is used as a disease-modifying antirheumatic medicine when ongoing control of autoimmune inflammation is needed.

Several treatment approaches exist for rheumatoid arthritis and psoriatic arthritis, and Arava is one option within DMARD therapy. Choice depends on disease severity, liver risk, pregnancy plans, prior response, and whether extra-articular symptoms are present.

Arava’s place is often as a once-daily oral DMARD when immune modulation is needed and injection therapy is not preferred. Its limitation is liver and pregnancy risk management, and the long persistence of its active metabolite means side effects may not resolve instantly after stopping.

People make predictable mistakes with Arava, and they often lead to avoidable side effects or disappointing results.

• Stopping after 2–3 weeks because pain relief wasn’t immediate, then calling it “ineffective.” DMARDs need time to change immune activity.
• Doubling the next dose after forgetting one day, which increases diarrhea, dizziness, and abnormal labs.
• Using alcohol heavily while on therapy and then being surprised by ALT and AST elevations.
• Ignoring early warning signs like persistent cough or shortness of breath, which needs prompt assessment because interstitial lung disease has been reported with leflunomide.
• Starting supplements or herbal products marketed for “detox” or “liver cleanse.” These can complicate liver monitoring and add hepatotoxic risk.

One more nuance I see often: patients focus only on joint pain scores and miss functional markers such as grip strength in the morning or time-to-walk comfortably, which are often the first domains to improve.

In rheumatology clinics, Arava is often framed as a “controller” DMARD: it aims to reduce flare frequency, morning stiffness, and swelling, while also slowing joint damage progression. Clinicians like that it is once daily and does not require injections, which improves adherence for many patients who struggle with complex schedules.

Doctors also set boundaries early: Arava is not a good fit if liver risk is high, if pregnancy is planned, or if there is a history of severe recurrent infections. A pattern clinicians recognize is that patients feel better, stop the medicine for a few weeks, and then flare hard; with immune-modulating therapy, stop–start use tends to destabilize disease control and makes side effects harder to interpret over time.

Another practical point doctors raise is blood pressure: even people with previously normal readings can drift upward on leflunomide, so hypertension screening becomes part of routine follow-up. This aligns with safety information assessed by regulators such as the EMA for leflunomide-containing products ^[3].